Twist Bioscience Co. (NASDAQ:TWST) Insider Dennis Cho Sells 709 Shares

Twist Bioscience Co. (NASDAQ:TWST) insider Dennis Cho sold 709 shares of the firm’s stock in a transaction dated Monday, August 5th. The stock was sold at an average price of $39.93, for a total value of $28,310.37. Following the completion of the transaction, the insider now owns 78,996 shares of the company’s stock, valued at $3,154,310.28. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Dennis Cho also recently made the following trade(s):

• On Tuesday, July 2nd, Dennis Cho sold 126 shares of Twist Bioscience stock. The stock was sold at an average price of $48.00, for a total value of $6,048.00.
• On Thursday, June 20th, Dennis Cho sold 234 shares of Twist Bioscience stock. The stock was sold at an average price of $49.41, for a total value of $11,561.94.
• On Friday, June 14th, Dennis Cho sold 95 shares of Twist Bioscience stock. The stock was sold at an average price of $51.04, for a total value of $4,848.80.
• On Thursday, June 6th, Dennis Cho sold 276 shares of Twist Bioscience stock. The stock was sold at an average price of $51.33, for a total value of $14,167.08.

Twist Bioscience Stock Performance

Shares of NASDAQ:TWST traded down $1.45 during trading on Friday, reaching $43.97. The stock had a trading volume of 944,659 shares, compared to its average volume of 1,050,882. The business has a fifty day moving average price of $50.93 and a 200-day moving average price of $41.70. The stock has a market cap of $2.58 billion, a PE ratio of -13.09 and a beta of 1.80. Twist Bioscience Co. has a 1-year low of $14.42 and a 1-year high of $60.90.

Twist Bioscience (NASDAQ:TWST) last issued its quarterly earnings results on Friday, August 2nd. The company reported ($1.47) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.71). The firm had revenue of $81.50 million during the quarter, compared to analyst estimates of $77.40 million. Twist Bioscience had a negative return on equity of 32.17% and a negative net margin of 74.63%. The business’s revenue was up 27.7% on a year-over-year basis. During the same period in the prior year, the firm earned ($1.01) earnings per share. Sell-side analysts expect that Twist Bioscience Co. will post -3.13 earnings per share for the current year.

Hedge Funds Weigh In On Twist Bioscience

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. EdgeRock Capital LLC acquired a new position in Twist Bioscience during the fourth quarter worth $30,000. Blue Trust Inc. boosted its stake in Twist Bioscience by 2,912.8% during the second quarter. Blue Trust Inc. now owns 1,175 shares of the company’s stock worth $58,000 after buying an additional 1,136 shares during the last quarter. DekaBank Deutsche Girozentrale acquired a new position in Twist Bioscience during the second quarter worth $61,000. Nisa Investment Advisors LLC raised its position in Twist Bioscience by 31.3% in the second quarter. Nisa Investment Advisors LLC now owns 2,288 shares of the company’s stock valued at $113,000 after purchasing an additional 546 shares during the period. Finally, CWM LLC raised its position in Twist Bioscience by 27.4% in the second quarter. CWM LLC now owns 2,437 shares of the company’s stock valued at $120,000 after purchasing an additional 524 shares during the period.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on TWST shares. The Goldman Sachs Group lifted their price target on Twist Bioscience from $45.00 to $55.00 and gave the company a “buy” rating in a research report on Tuesday, July 9th. Evercore ISI lifted their price target on Twist Bioscience from $46.00 to $50.00 and gave the company an “outperform” rating in a research report on Friday, May 3rd. Scotiabank lifted their price target on Twist Bioscience from $43.00 to $48.00 and gave the company a “sector outperform” rating in a research report on Monday, May 6th. Guggenheim started coverage on Twist Bioscience in a research report on Tuesday, June 4th. They set a “buy” rating and a $53.00 price target for the company. Finally, TD Cowen lifted their price target on Twist Bioscience from $55.00 to $65.00 and gave the company a “buy” rating in a research report on Thursday, June 13th. One analyst has rated the stock with a sell rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $48.22.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.